A Study of CBP-1008 in Patients With Advanced Solid Tumor
Condition: Advanced Solid Tumor · Sponsor: Coherent Biopharma (Suzhou) Co., Ltd.
About this study
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1008, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
Talk to the study team
Jiangang Yu · +86 512 85550899 · jiangang.yu@coherentbio.com
Always discuss trial participation with your own doctor first.
Locations (3)
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04740398